| Title | Targeting Serine in Cancer: Is Two Better Than One? |
| Publication Type | Journal Article |
| Year of Publication | 2021 |
| Authors | Buqué A, Galluzzi L, Montrose DC |
| Journal | Trends Cancer |
| Volume | 7 |
| Issue | 8 |
| Pagination | 668-670 |
| Date Published | 2021 Aug |
| ISSN | 2405-8025 |
| Keywords | Antimetabolites, Antineoplastic, Cell Line, Tumor, Combined Modality Therapy, Diet, Protein-Restricted, Dietary Proteins, Humans, Neoplasms, Phosphoglycerate Dehydrogenase, Phosphoric Monoester Hydrolases, Serine, Transaminases, Xenograft Model Antitumor Assays |
| Abstract | Several recent preclinical studies have demonstrated that simultaneously blocking exogenous and endogenous sources of serine in malignant cells mediates superior anticancer effects as compared with limiting either source alone. Here, we critically summarize key developments in targeting serine to treat cancer and discuss persisting challenges for implementing such a therapeutic approach in patients. |
| DOI | 10.1016/j.trecan.2021.06.004 |
| Alternate Journal | Trends Cancer |
| PubMed ID | 34219053 |
| PubMed Central ID | PMC9097339 |
| Grant List | K22 CA226033 / CA / NCI NIH HHS / United States |